Edition:
India

Vaxart Inc (VXRT.OQ)

VXRT.OQ on NASDAQ Stock Exchange Capital Market

0.74USD
24 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.74
Open
--
Day's High
--
Day's Low
--
Volume
2,260
Avg. Vol
156,583
52-wk High
$7.60
52-wk Low
$0.73

Latest Key Developments (Source: Significant Developments)

Vaxart Announces Pricing Of Underwritten Public Offering
Tuesday, 9 Apr 2019 

April 9 (Reuters) - Vaxart Inc ::VAXART ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING.VAXART INC - PUBLIC OFFERING TO PURCHASE ONE SHARE OF COMMON STOCK AT AN EFFECTIVE PRICE TO PUBLIC OF $1.10 PER SHARE AND ACCOMPANYING COMMON WARRANT..VAXART - PRICED OFFERING OF ABOUT 9.1 MILLION COMMON SHARES, COMMON WARRANTS TO BUY UP TO ABOUT 9.1 MILLION SHARES OF COMMON STOCK.  Full Article

Vaxart Inc Files For Common Stock Offering Of Up To $11.5 Mln
Thursday, 7 Feb 2019 

Feb 6 (Reuters) - Vaxart Inc ::VAXART INC FILES FOR COMMON STOCK OFFERING OF UP TO $11.5 MILLION - SEC FILING.  Full Article

Vaxart - John Harland, resigned as CFO, treasurer and secretary of co - SEC Filing
Wednesday, 19 Dec 2018 

Dec 18 (Reuters) - Vaxart Inc ::VAXART - ON DEC 12, 2018, JOHN M. HARLAND, RESIGNED AS CFO, TREASURER AND SECRETARY OF CO EFFECTIVE DECEMBER 31, 2018 - SEC FILING.VAXART - EFFECTIVE JANUARY 1, 2019, WOUTER W. LATOUR, M.D., PRESIDENT AND CEO, WILL ALSO SERVE AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Vaxart Reports Topline Results From Phase 2 Trial Of Teslexivir For The Treatment Of Condyloma
Monday, 4 Jun 2018 

June 4 (Reuters) - Vaxart Inc ::VAXART REPORTS TOPLINE RESULTS FROM PHASE 2 TRIAL OF TESLEXIVIR FOR THE TREATMENT OF CONDYLOMA.VAXART REPORTS TOPLINE RESULTS FROM PHASE 2 TRIAL OF TESLEXIVIR FOR THE TREATMENT OF CONDYLOMA.PRIMARY EFFICACY ENDPOINT NOT ACHIEVED - POSITIVE TREND IN TWO IMPORTANT SUBGROUPS.SAFETY AND TOLERABILITY PROFILE COMPARABLE TO PLACEBO.PRIMARY EFFICACY ENDPOINT NOT ACHIEVED.NO SERIOUS ADVERSE EVENTS WERE OBSERVED.  Full Article

Vaxart Q1 Net Income Per Common Share $0.49
Wednesday, 16 May 2018 

May 15 (Reuters) - Vaxart Inc ::VAXART ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q1 REVENUE $1.5 MILLION VERSUS $2.3 MILLION.QTRLY NET INCOME PER COMMON SHARE $0.49.  Full Article

Aviragen Adjourns Special Meeting Of Stockholders
Saturday, 10 Feb 2018 

Feb 9 (Reuters) - Aviragen Therapeutics Inc ::AVIRAGEN ADJOURNS SPECIAL MEETING OF STOCKHOLDERS TO ALLOW STOCKHOLDERS TO CONSIDER IMPROVED MERGER DEAL TERMS.SAYS ‍SPECIAL MEETING OF STOCKHOLDERS HAS BEEN FURTHER ADJOURNED TO 10:00 AM, EST ON FEBRUARY 13, 2018​.SAYS ‍ALSO ANNOUNCED TODAY THAT CAS GROUP HAS AGREED TO SUPPORT MERGER OF COMPANY AND VAXART​.SAYS ‍CAS GROUP AGREED TO WITHDRAW ITS NOMINATION OF DIRECTORS IN CONNECTION WITH NEXT ANNUAL MEETING OF STOCKHOLDERS OF CO.  Full Article

Aviragen And Vaxart Amend Terms Of Merger Agreement To Increase The Value For Aviragen Stockholders
Thursday, 8 Feb 2018 

Feb 7 (Reuters) - Aviragen Therapeutics Inc ::AVIRAGEN AND VAXART AMEND TERMS OF MERGER AGREEMENT TO INCREASE THE VALUE FOR AVIRAGEN STOCKHOLDERS.AVIRAGEN THERAPEUTICS INC - AVIRAGEN STOCKHOLDERS WOULD NOW OWN 49% OF COMBINED COMPANY, UP FROM 40% UNDER PREVIOUS AGREEMENT.AVIRAGEN THERAPEUTICS INC - AMENDED AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES.AVIRAGEN THERAPEUTICS INC - AVIRAGEN BOARD RECOMMENDS AVIRAGEN STOCKHOLDERS VOTE FOR MERGER AT SPECIAL MEETING OF STOCKHOLDERS ON FEBRUARY 9, 2018.AVIRAGEN THERAPEUTICS INC - ‍INTENDS TO RECONVENE SPECIAL MEETING OF STOCKHOLDERS TO VOTE ON PROPOSED MERGER ON FEB 9, 2018 AT 12:00 PM EST​.  Full Article

Digirad, East Hill File Preliminary Proxy Statement Related To Aviragen, Vaxart Proposed Merger
Saturday, 20 Jan 2018 

Jan 19 (Reuters) - :DIGIRAD, EAST HILL FILE PRELIMINARY PROXY STATEMENT RELATED TO AVIRAGEN THERAPEUTICS, VAXART PROPOSED MERGER - SEC FILING.DIGIRAD, EAST HILL URGE AVIRAGEN THERAPEUTICS SHAREHOLDERS TO VOTE AGAINST CO'S PROPOSED MERGER WITH VAXART.  Full Article

Thomas Clay Reports A 8.3 Pct Stake In Aviragen Therapeutics
Saturday, 30 Dec 2017 

Dec 29 (Reuters) - Aviragen Therapeutics Inc ::THOMAS CLAY REPORTS A 8.3 PCT STAKE IN AVIRAGEN THERAPEUTICS INC AS OF DEC 29 - SEC FILING.THOMAS CLAY- PURCHASED AVIRAGEN SHARES BASED ON BELIEF THAT WHEN PURCHASED, SHARES WERE "UNDERVALUED", REPRESENTED ATTRACTIVE "INVESTMENT OPPORTUNITY"‍​.THOMAS CLAY SAYS INTENDS TO SUBMIT DIRECTOR NOMINATIONS TO AVIRAGEN'S BOARD TO BE CONSIDERED AT NEXT STOCKHOLDER MEETING HELD TO ELECT DIRECTORS.THOMAS CLAY SAYS DO NOT BELIEVE PROPOSED MERGER BETWEEN AVIRAGEN, VAXART IS IN "BEST INTEREST" OF AVIRAGEN OR ITS STOCKHOLDERS.  Full Article

Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Aviragen Therapeutics Inc ::AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA.AVIRAGEN THERAPEUTICS INC- ‍EXPECTS TO REPORT TOP-LINE DATA FROM TRIAL IN Q2 OF 2018​.  Full Article